Tag: Cyp3a inhibitors

Zanubrutinib, a targeted Bruton's tyrosine kinase (BTK) inhibitor, is a vital treatment for certain B-cell malignancies. However, like many medications, it is susceptible to drug-drug interactions that can significantly alter its effectiveness or increase the risk of serious side effects. Understanding **what drugs interact with zanubrutinib** is crucial for patient safety and treatment optimization.

Approved by the FDA in January 2025, suzetrigine (brand name Journavx) offers a non-opioid alternative for acute pain relief. However, like all medications, it is not suitable for everyone. Understanding **who should not take suzetrigine** is crucial for patient safety and preventing serious adverse effects.